Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kyntra Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.432 Please be advised that today's conference is being recorded. 00:00:03.432 -- 00:00:07.994 I would now like to hand the conference over to your speaker today, Gaia Shamis of Lifespy 00:00:07.994 -- 00:00:10.996 Advisors. Please go ahead. 00:00:10.996 -- 00:00:14.097 Thank you, Latonya, and good afternoon, everyone. 00:00:14.097 -- 00:00:19.579 Thank you for joining today to discuss Kintra Bio's second quarter 2026 financial 00:00:19.579 -- 00:00:23.901 and business results. I'm Gaia Shamis from Lifespy Advisors. 00:00:23.901 -- 00:00:28.997 Joining me on today's call are Thane Wettig, Chief Executive Officer, David 00:00:28.997 -- 00:00:34.161 DeLucia, Chief Financial Officer, and Carol Gadom, Vice President of Product 00:00:34.161 -- 00:00:35.621 Development. 00:00:35.621 -- 00:00:39.604 Following the prepared remarks, we will open the call to your questions. 00:00:39.604 -- 00:00:43.827 I would like to remind you that remarks made on today's call include forward-looking 00:00:43.827 -- 00:00:48.890 statements about Kintra's bio. Such statements may include, but are not limited 00:00:48.890 -- 00:00:54.287 to, collaborations with AstraZeneca and Astellas, financial guidance, 00:00:54.287 -- 00:00:59.729 The Initiation, Enrollment, Design, Conduct and Results of Clinical Trials, 00:00:59.729 -- 00:01:05.990 Regulatory Strategies and Potential Regulatory Results, Research and Development Activities, 00:01:05.990 -- 00:01:11.072 Commercial Results and Results of Operations, Risks Related to Our Business, and 00:01:11.072 -- 00:01:16.113 Certain Other Business Matters. Each forward-looking statement is subject to risks and 00:01:16.113 -- 00:01:20.635 uncertainties that could cause actual results and events to differ materially from th...